Related Experiment Video
Updated: Apr 25, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
Inhibition of glutamine synthetase: a potential drug target in Mycobacterium tuberculosis
Sherry L Mowbray1, Muthu K Kathiravan2, Abhishek A Pandey3
1Department of Cell and Molecular Biology, Science for Life Laboratory, Uppsala University, Biomedical Center, Box 596, SE-751 24 Uppsala, Sweden.
Abstract:
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Globally, tuberculosis is second only to AIDS in mortality and the disease is responsible for over 1.3 million deaths each year. The impractically long treatment schedules (generally 6-9 months) and unpleasant side effects of the current drugs often lead to poor patient compliance, which in turn has resulted in the emergence of multi-, extensively- and totally-drug resistant strains. The development of new classes of anti-tuberculosis drugs and new drug targets is of global importance, since attacking the bacterium using multiple strategies provides the best means to prevent resistance. This review presents an overview of the various strategies and compounds utilized to inhibit glutamine synthetase, a promising target for the development of drugs for TB therapy.
More Related Videos
Related Concept Videos
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial DNA Synthesis
Inhibitors of Viral Protein Synthesis
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Gene Regulation in Microbial Communities: Quorum Sensing

